NCT02722265View on ClinicalTrials.gov

Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

368

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

July 8, 2017

Study Completion Date

July 8, 2017

Conditions
Essential Hypertension
Interventions
DRUG

CS-3150

CS-3150 2.5mg to 5mg, orally, once daily for 28 or 52 weeks

Trial Locations (1)

Unknown

Osaka

Sponsors
All Listed Sponsors
lead

Daiichi Sankyo Co., Ltd.

INDUSTRY